Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain

  1. Sanchez-Luna, M.
  2. Burgos-Pol, R.
  3. Oyagüez, I.
  4. Figueras-Aloy, J.
  5. Sánchez-Solís, M.
  6. Martinón-Torres, F.
  7. Carbonell-Estrany, X.
Journal:
BMC Infectious Diseases

ISSN: 1471-2334

Year of publication: 2017

Volume: 17

Issue: 1

Type: Article

DOI: 10.1186/S12879-017-2803-0 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals